• linkedin
  • Increase Font
  • Sharebar

    FDA approves another testosterone replacement gel

    The FDA has approved a new testosterone gel formulation, marking the agency’s second approval of a testosterone replacement therapy in the course of a week.

    On June 4, a topical testosterone gel to be marketed under the brand name Vogelxo was approved. A week earlier, as previously reported, the FDA approved a testosterone nasal gel known as Natesto.

    Both agents are indicated for the treatment of adult males with hypogonadism. Their approvals come at a time when the FDA is investigating testosterone agents for a possible increased risk of cardiac events.

    In a randomized, placebo-controlled study of Vogelxo, of 192 hypogonadal men (those with morning testosterone ≤300 ng/dL) who were appropriately titrated with the testosterone gel and who had sufficient data for analysis, 74% achieved an average serum testosterone level within the normal range (300 to 1,000 ng/dL) after 3 months of treatment, according to the drug’s package insert.

    The gel is applied to the shoulders and/or upper arms. Upsher-Smith Laboratories, Inc., the drug’s maker, said in a press release that it is preparing to launch Vogelxo in “the near future.”

    The FDA investigation of low T agents was announced in January following the publication of two studies (PLOS ONE [published online Jan. 29, 2014] and JAMA 2013; 310:1829-36), both of which reported an increased risk of cardiac events, including heart attack and stroke, associated with testosterone therapy. The studies have drawn widespread criticism, and a group known as the Androgen Study Group has called for retraction of the JAMA article, citing “gross data mismanagement.”

    More on testosterone/hypogonadism

    TRT shows benefit, no harm in post-RP patients

    Study: Testosterone linked to progressive weight loss

    Estradiol boosts libido in men receiving testosterone

     


     

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll